The previous Johnson & Johnson (NYSE:JNJ) subsidiary, recently sold to Cardinal Health (NYSE:CAH) said it will bring the Outback Elite re-entry catheter to the U.S., Japan and Europe, and the Elitecross Support catheter to the U.S.
“New and dedicated CTO crossing wires, re-entry devices and crossing catheters, combined with advancing technique have led to a significant improvement in success rates of CTO treatment in recent years. The expanded Cordis Crossing portfolio enables physicians to further improve treatment success, and deliver the best possible care to the patients that rely on us every day,” Dr. Jihad Mustapha of Wyoming, Mich.’s Metro Health Hospital said in a press release.
CTO crossing devices are designed to treat and cross through blockages in vessels where plaque accumulation is so severe the vessel is completely, or nearly completely, blocked, the company said.
“We are pleased to continue delivering advancement in a market segment that we have been dedicated to for over a decade. The launch of the expanded Cordis Crossing Portfolio further strengthens and differentiates our product portfolio and illustrates our commitment to innovation within lower extremity treatment technologies,” Cordis president David Wilson said in prepared remarks.
Johnson & Johnson said in May that it accepted a binding offer worth about $2 billion for its Cordis stent-making arm from Cardinal Health. The New Brunswick, N.J.-based healthcare giant said it expects the deal to close “towards the end of 2015.”
The $1.94 billion deal, which is worth some $1.59 billion net of tax benefits, offers annual synergies in excess of $100 million by the end of fiscal 2018, Cardinal Health said in announcing the deal last March.